Food Noise: What Actually Quiets It
“Food noise” is the constant, intrusive mental chatter about food that GLP-1 and amylin drugs turn down. Here's the real mechanism behind the retatrutide + cagrilintide (“Reta-Cag”) stack people use for it — and the honest limits of the evidence.
How It Works
The persistent, intrusive mental chatter about food — cravings, preoccupation, “what’s next to eat.” It’s now a defined, measurable construct in the literature, with validated questionnaires to quantify it (PMID 40628707, 41101555). GLP-1 and amylin drugs are what most people credit with turning it down.
A triple GIP/GLP-1/glucagon receptor agonist (LY3437943). In its Phase 2 obesity trial it drove large weight loss across 1–12 mg weekly doses (PMID 37366315), acting on the appetite and reward circuits central to food noise. Investigational — not FDA-approved.
A long-acting amylin analog that signals satiety through hindbrain and hypothalamic pathways — a different axis than GLP-1. This is the “food-noise closer” people add on top of reta. Dosed far lower than retatrutide — a 0.3–4.5 mg weekly trial range (with up to a 6-week escalation), and in practice about 0.25–1.5 mg versus 4–8 mg of reta (PMID 34798060).
Pre-mixed 1:1 reta:cagri blends force cagrilintide up to the retatrutide dose. Set reta at 4–8 mg and a 1:1 blend delivers 4–8 mg cagrilintide cold — at or above the highest dose ever studied, with no titration. That is exactly why a reported 2 mg/2 mg blend caused five straight days of vomiting. Dose them separately.
What the Data Shows
Key Takeaways
- “Food noise” is a real, now-measurable construct — validated tools to quantify it exist (PMID 40628707, 41101555).
- Cagrilintide (amylin) and retatrutide (GIP/GLP-1/glucagon) each have Phase 2+ weight-loss trial data and act on different appetite pathways.
- Cagrilintide works at much lower doses than retatrutide — a 0.3–4.5 mg weekly trial range (up to a 6-week escalation); in practice about 0.25–1.5 mg vs reta at 4–8 mg (roughly 10x).
- The only amylin+incretin combo with real trial data is CagriSema (cagrilintide + semaglutide) — REDEFINE 1 & 2 (PMID 40544433, 40544432).
- There are ZERO published trials of the retatrutide + cagrilintide (“Reta-Cag”) combination — every claim about the stack is extrapolation or anecdote.
- A pre-mixed 1:1 reta:cagri blend overdoses the cagrilintide — dose them separately and titrate cagri up slowly from ~0.25 mg; never buy a 1:1 blend.
- No confirmed weight-loss percentage exists for Reta-Cag specifically — anyone quoting one is guessing.
- Claims that cagrilintide “dissolves amyloid plaque” or cures addictions are unsupported — ignore them.
- Retatrutide and cagrilintide are both investigational — neither is FDA-approved, and combination products are unregulated.
Frequently Asked Questions
What is food noise?
Food noise is the constant, intrusive mental chatter about food — cravings, preoccupation, and thoughts about the next meal. It is now a defined and measurable construct in the medical literature, with validated questionnaires to quantify it (PMID 40628707, 41101555). GLP-1 and amylin medications are what most people credit with quieting it.
What is the “Reta-Cag” stack?
“Reta-Cag” is an off-label community combination of retatrutide (a GIP/GLP-1/glucagon triple agonist) and cagrilintide (a long-acting amylin analog), used to control appetite and food noise. Important: there are no published clinical trials of this exact combination. The only amylin+incretin combo with trial data is CagriSema — cagrilintide plus semaglutide, not retatrutide.
Is a 1:1 retatrutide/cagrilintide blend safe?
No — a fixed 1:1 blend is the main danger people report. Cagrilintide is dosed several times lower than retatrutide by trial range (0.3–4.5 mg vs 1–12 mg) and about ten times lower in practice (~0.25–1.5 mg vs 4–8 mg), with up to a 6-week escalation. A 1:1 blend forces the cagrilintide up to the retatrutide dose (4–8 mg), delivering it cold at or above the highest dose ever studied. A reported 2 mg/2 mg blend caused five straight days of vomiting. If used together, they should be dosed separately with cagrilintide titrated up slowly.
Does Reta-Cag work better than CagriSema?
There is no way to know — Reta-Cag has never been studied in a trial, while CagriSema (cagrilintide + semaglutide) has Phase 3 data (REDEFINE 1 & 2, PMID 40544433, 40544432). Retatrutide is a more powerful weight-loss agent than semaglutide in its own trials, so the combination is mechanistically interesting — but “interesting” is not “proven.”
Are retatrutide or cagrilintide FDA-approved?
No. As of 2026 both are investigational and not FDA-approved. Retatrutide is in late-stage obesity trials; cagrilintide is furthest along inside the CagriSema program. Neither is available as an approved medicine, and combination products are unregulated.
🔬 Research-Grade Source
Swiss Chems publishes third-party HPLC COAs for selected products — vendor-published, a claim to verify. HighPeptides' primary vendor reference for peptides.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Peer-Reviewed References
This content is for educational purposes only. It is not medical advice. Always consult a qualified healthcare provider. Research use only.